Immune Checkpoint Proteins: Exploring Their Therapeutic Potential to Regulate Atherosclerosis

Overview

Journal Br J Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 2017 Apr 4

PMID 28369782

Citations 33

Authors

A C Foks

J Kuiper

Affiliations

Soon will be listed here.

Abstract

Linked Articles: This article is part of a themed section on Targeting Inflammation to Reduce Cardiovascular Disease Risk. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.22/issuetoc and http://onlinelibrary.wiley.com/doi/10.1111/bcp.v82.4/issuetoc.

Citing Articles

Immune checkpoint inhibitors and myocardial infarction.

Juhasz V, Suero-Abreu G, Neilan T J Thromb Thrombolysis. 2025; .

PMID: 40064838 DOI: 10.1007/s11239-025-03081-7.

Impact of statin therapy on CD40:CD40L signaling: mechanistic insights and therapeutic opportunities.

Askarizadeh F, Karav S, Jamialahmadi T, Sahebkar A Pharmacol Rep. 2024; 77(1):43-71.

PMID: 39680334 DOI: 10.1007/s43440-024-00678-2.

Machine learning models based on fluid immunoproteins that predict non-AIDS adverse events in people with HIV.

Premeaux T, Bowler S, Friday C, Moser C, Hoenigl M, Lederman M iScience. 2024; 27(6):109945.

PMID: 38812553 PMC: 11134891. DOI: 10.1016/j.isci.2024.109945.

Single-cell T cell receptor sequencing of paired human atherosclerotic plaques and blood reveals autoimmune-like features of expanded effector T cells.

Depuydt M, Schaftenaar F, Prange K, Boltjes A, Hemme E, Delfos L Nat Cardiovasc Res. 2024; 2(2):112-125.

PMID: 38665903 PMC: 11041750. DOI: 10.1038/s44161-022-00208-4.

A comprehensive review on immune checkpoint inhibitors induced cardiotoxicity characteristics and associated factors.

Ndjana Lessomo F, Mandizadza O, Mukuka C, Wang Z Eur J Med Res. 2023; 28(1):495.

PMID: 37941006 PMC: 10631013. DOI: 10.1186/s40001-023-01464-1.

References

Yin C, Mohanta S, Srikakulapu P, Weber C, Habenicht A . Artery Tertiary Lymphoid Organs: Powerhouses of Atherosclerosis Immunity. Front Immunol. 2016; 7:387. PMC: 5056324. DOI: 10.3389/fimmu.2016.00387. View

Kim W, Bae E, Kang Y, Bae H, Hong S, Lee J . Glucocorticoid-induced tumour necrosis factor receptor family related protein (GITR) mediates inflammatory activation of macrophages that can destabilize atherosclerotic plaques. Immunology. 2006; 119(3):421-9. PMC: 1819571. DOI: 10.1111/j.1365-2567.2006.02453.x. View

Hou N, Zhao D, Liu Y, Gao L, Liang X, Liu X . Increased expression of T cell immunoglobulin- and mucin domain-containing molecule-3 on natural killer cells in atherogenesis. Atherosclerosis. 2012; 222(1):67-73. DOI: 10.1016/j.atherosclerosis.2012.02.009. View

Sugamura K, Ishii N, Weinberg A . Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. Nat Rev Immunol. 2004; 4(6):420-31. DOI: 10.1038/nri1371. View

Kim W, Kang Y, Suk K, Park J, Kwon B, Lee W . Comparative analysis of the expression patterns of various TNFSF/TNFRSF in atherosclerotic plaques. Immunol Invest. 2008; 37(4):359-73. DOI: 10.1080/08820130802123139. View

Swallow M, Wallin J, Sha W . B7h, a novel costimulatory homolog of B7.1 and B7.2, is induced by TNFalpha. Immunity. 1999; 11(4):423-32. DOI: 10.1016/s1074-7613(00)80117-x. View

de Boer O, van der Meer J, Teeling P, van der Loos C, van der Wal A . Low numbers of FOXP3 positive regulatory T cells are present in all developmental stages of human atherosclerotic lesions. PLoS One. 2007; 2(8):e779. PMC: 1945014. DOI: 10.1371/journal.pone.0000779. View

Bettelli E, Carrier Y, Gao W, Korn T, Strom T, Oukka M . Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006; 441(7090):235-8. DOI: 10.1038/nature04753. View

Olofsson P, Soderstrom L, Wagsater D, Sheikine Y, Ocaya P, Lang F . CD137 is expressed in human atherosclerosis and promotes development of plaque inflammation in hypercholesterolemic mice. Circulation. 2008; 117(10):1292-301. DOI: 10.1161/CIRCULATIONAHA.107.699173. View

10.

Lutgens E, Daemen M . CD40-CD40L interactions in atherosclerosis. Trends Cardiovasc Med. 2002; 12(1):27-32. DOI: 10.1016/s1050-1738(01)00142-6. View

11.

Baum P, Gayle 3rd R, Ramsdell F, Srinivasan S, Sorensen R, Watson M . Molecular characterization of murine and human OX40/OX40 ligand systems: identification of a human OX40 ligand as the HTLV-1-regulated protein gp34. EMBO J. 1994; 13(17):3992-4001. PMC: 395319. DOI: 10.1002/j.1460-2075.1994.tb06715.x. View

12.

Shi J, Wang L, Zhu Y, Zhao C, Liu W, Jiang S . OX40 ligand levels and high-sensitivity C-reactive protein levels in blood from local coronary plaque and the femoral artery in patients with acute coronary syndrome or stable angina. J Int Med Res. 2011; 39(4):1275-83. DOI: 10.1177/147323001103900415. View

13.

Veldhoen M, Hocking R, Atkins C, Locksley R, Stockinger B . TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity. 2006; 24(2):179-89. DOI: 10.1016/j.immuni.2006.01.001. View

14.

Pollok K, Kim Y, Hurtado J, Zhou Z, Kim K, Kwon B . 4-1BB T-cell antigen binds to mature B cells and macrophages, and costimulates anti-mu-primed splenic B cells. Eur J Immunol. 1994; 24(2):367-74. DOI: 10.1002/eji.1830240215. View

15.

Foks A, van Puijvelde G, Bot I, Ter Borg M, Habets K, Johnson J . Interruption of the OX40-OX40 ligand pathway in LDL receptor-deficient mice causes regression of atherosclerosis. J Immunol. 2013; 191(9):4573-80. DOI: 10.4049/jimmunol.1200708. View

16.

Vinay D, Kwon B . Role of 4-1BB in immune responses. Semin Immunol. 1998; 10(6):481-9. DOI: 10.1006/smim.1998.0157. View

17.

Taleb S, Tedgui A, Mallat Z . IL-17 and Th17 cells in atherosclerosis: subtle and contextual roles. Arterioscler Thromb Vasc Biol. 2014; 35(2):258-64. DOI: 10.1161/ATVBAHA.114.303567. View

18.

van Puijvelde G, Hauer A, de Vos P, van den Heuvel R, van Herwijnen M, van der Zee R . Induction of oral tolerance to oxidized low-density lipoprotein ameliorates atherosclerosis. Circulation. 2006; 114(18):1968-76. DOI: 10.1161/CIRCULATIONAHA.106.615609. View

19.

Perkins D, Wang Z, Donovan C, He H, Mark D, Guan G . Regulation of CTLA-4 expression during T cell activation. J Immunol. 1996; 156(11):4154-9. View

20.

Gewaltig J, Kummer M, Koella C, Cathomas G, Biedermann B . Requirements for CD8 T-cell migration into the human arterial wall. Hum Pathol. 2008; 39(12):1756-62. DOI: 10.1016/j.humpath.2008.04.018. View